Title:
CD39/CD73 BISPECIFIC ANTIGEN BINDING PROTEIN AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/236968
Kind Code:
A8
Abstract:
Provided is an isolated antigen-binding protein, which contains a first binding domain and a second binding domain, wherein the first binding domain is capable of binding to a CD39 protein, and the second binding domain is capable of binding to a CD73 protein. Also provided are a nucleic acid molecule encoding the isolated antigen-binding protein, a vector and a cell containing the nucleic acid molecule, a pharmaceutical composition containing the isolated antigen-binding protein, a method for preparing the isolated antigen-binding protein, and the use of the isolated antigen-binding protein.
Inventors:
XU JINGEN (CN)
WANG SHAOJIE (CN)
ZHU XIANGYANG (CN)
ZHAN YIFAN (CN)
YU HAIJIA (CN)
ZHU XI (CN)
ZHANG LEI (CN)
CHEN SHI (CN)
CUI XIAOPEI (CN)
WANG SHAOJIE (CN)
ZHU XIANGYANG (CN)
ZHAN YIFAN (CN)
YU HAIJIA (CN)
ZHU XI (CN)
ZHANG LEI (CN)
CHEN SHI (CN)
CUI XIAOPEI (CN)
Application Number:
PCT/CN2023/098744
Publication Date:
January 25, 2024
Filing Date:
June 07, 2023
Export Citation:
Assignee:
SHANGHAI HUAOTA BIOPHARMACEUTICAL CO LTD (CN)
HUABO BIOPHARM SHANGHAI CO LTD (CN)
HUABO BIOPHARM SHANGHAI CO LTD (CN)
International Classes:
C07K16/40; A61K39/00; A61P35/00; C07K16/28; C12N15/13
Attorney, Agent or Firm:
SHANGHAI DIANSHI PARTNERS , P.C. (CN)
Download PDF: